Scalable Transient CHO Method that in 7-12 days may become Stable Cell Pools & Stable Lines for Quantities needed in Toxicology Studies

Poster presented at BioProcess 2016
Joseph Abad2, James Brady2, Weili Wang2, Joe Machamer1, Ana Sirianni1, Sam Ellis1
1Thomson Instrument Company, Oceanside, CA
2Maxcyte, Gaithersburg, MD

Increasing competition in recombinant antibody and protein drug discovery has resulted from the U.S. Patent Office instituting 'First to File'. As a result, the time frame for generating patentable biologic molecules has been extremely compressed. Companies are now forced to utilize methods that can significantly speed transient hits through to stable pools and clones. Thomson Instrument Company and MaxCyte will show new methodology to produce scalable recombinant antibodies and proteins that will lead to faster and higher titers with excellent glycosylation. Our technical advancements in shake flask design, and improvements in transfection significantly shorten timelines and improve product quality allowing for faster filing.

Related Application Notes

Optimum Growth™ Protocol for Insect Cells

... Sf9 and Sf21 insect cells are cell lines commonly used for expression of recombinant proteins using baculovirus sys...

See Application Note

Simplified Sample Prep for Open Access SEC-HPLC Detection using the Thomson Filter Vials

Routine analysis of samples containing cell culture media and/or supernatant by HPLC can lead to performance issues and...

See Application Note

Comparison of the Rapid Clear® Cap 3000 (patented) vs GE Capsule Filters for clarifying monospecific IgG

Two methods to clarify 10L of post transfected IgG harvested from culture are compared. The culture was harvested on da...

See Application Note

Improved DNA Protocol for E.coli with Plasmid+® Media

Plasmid+® liquid media is an enriched media specifically designed for plasmid DNA production. Plasmid+® supports much h...

See Application Note

Title

Scalable Transient CHO Method that in 7-12 days may become Stable Cell Pools & Stable Lines for Quantities needed in Toxicology Studies

Description

Increasing competition in recombinant antibody and protein drug discovery has resulted from the U.S. Patent Office instituting 'First to File'. As a result, the time frame for generating patentable biologic molecules has been extremely compressed. Companies are now forced to utilize methods that can significantly speed transient hits through to st...

PDF Download

Product Used

Optimum Growth™ 125mL Flask

PTFE 0.2µm Vent Cap for Increased Aeration | Sterile

pn#931110

Related Products

© 2021 Thomson |
Solutions At Work™

LinkedIn